Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

Yazed AlRuthia; Khaled Hani Aburisheh; Sondus Ata; Raghad Bin Salleeh; Shahad B. Alqudhibi; Raghad B. Alqudhibi; Ziad Alkraidis; Hala Humood Alkhalaf; Abdulrahman Abdullah Almogirah; Muhammad Mujammami; Reem Al Khalifah

doi:10.1016/j.jsps.2024.102057

Citations

384

Views

Abstract not available for this publication.

Cite this Article (APA)

Yazed, A., Khaled, H. A., Sondus, A., Raghad, B. S., Shahad, B. A., Raghad, B. A., Ziad, A., Hala, H. A., Abdulrahman, A. A., Muhammad, M., Reem, A. K. (2024). Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia. Saudi Pharmaceutical Journal. https://doi.org/10.1016/j.jsps.2024.102057